Saki Ishikawa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Saki Ishikawa has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Taiki Suzuki
Department of Oral and Maxillofacial Surgery, Kanto Rosai Hospital, 1-1 Kizukisumiyoshicho, Kawasaki 211-8510, Japan
3 shared publications Takeshi Nomura
3 shared publicationsAkira Katakura
2 shared publicationsAyaka Tatsumi
2 shared publicationsSatoru Ogane
2 shared publicationsShiori Tanaka
2 shared publications
Latest Publications
- 19 February 2025
- Published by Elsevier in Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology
- Vol. 37 (5) , 895-899
Clinical efficacy and safety of tegafur, gimeracil, and oteracil potassium (S-1) monotherapy for incurable oral squamous cell carcinoma patients
- 19 February 2025
- Published by Elsevier in Journal of Oral and Maxillofacial Surgery, Medicine, and Pathology
- Vol. 37 (5) , 895-899
Clinical efficacy and safety of tegafur, gimeracil, and oteracil potassium (S-1) monotherapy for incurable oral squamous cell carcinoma patients
- 9 June 2024
- Published by Wiley in Oral Science International
- Vol. 22 (1)
The use of cetuximab for oral cancer and adverse events with different treatment regimens: A single‐center retrospective study over an 11‐year period
Background: The aim of this retrospective study was to assess the use and safety of cetuximab (C‐mab) monotherapy or combination therapy with various regimens for treating oral cancer in our hospital.Methods: The study comprised 53 patients diagnosed with oral cancer who underwent chemotherapy with C‐mab between January 2013 and December 2022 at the Oral Cancer Center, Tokyo Dental College. In total, 68 regimens were analyzed. The cumulative rate was determined by analyzing the timing and incidence of adverse events (AEs) with each regimen using a Kaplan–Meier curve.Results: The treatment regimens administered included the following: induction C‐mab + paclitaxel + carboplatin (ICT‐PCE, n = 7), C‐mab + radiotherapy (RT) (n = 22), C‐mab + cisplatin + fluorouracil (n = 7), C‐mab + paclitaxel + carboplatin (n = 1), C‐mab + paclitaxel (n = 16), C‐mab maintenance (n = 11), and four other cases. The total number of doses administered was 895.Conclusions: This retrospective study investigated the effectiveness of treatment regimens containing C‐mab for oral cancer and adverse reactions to these regimens. C‐mab is a crucial component of oral cancer treatment when used in multidrug therapy. C‐mab containing regimens may result in direct or indirect AEs. Ongoing, rigorous monitoring is essential to mitigate these events. Partnering with other departments can help to limit their severity.
- 9 June 2024
- Published by Wiley in Oral Science International
- Vol. 22 (1)
The use of cetuximab for oral cancer and adverse events with different treatment regimens: A single‐center retrospective study over an 11‐year period
Background: The aim of this retrospective study was to assess the use and safety of cetuximab (C‐mab) monotherapy or combination therapy with various regimens for treating oral cancer in our hospital.Methods: The study comprised 53 patients diagnosed with oral cancer who underwent chemotherapy with C‐mab between January 2013 and December 2022 at the Oral Cancer Center, Tokyo Dental College. In total, 68 regimens were analyzed. The cumulative rate was determined by analyzing the timing and incidence of adverse events (AEs) with each regimen using a Kaplan–Meier curve.Results: The treatment regimens administered included the following: induction C‐mab + paclitaxel + carboplatin (ICT‐PCE, n = 7), C‐mab + radiotherapy (RT) (n = 22), C‐mab + cisplatin + fluorouracil (n = 7), C‐mab + paclitaxel + carboplatin (n = 1), C‐mab + paclitaxel (n = 16), C‐mab maintenance (n = 11), and four other cases. The total number of doses administered was 895.Conclusions: This retrospective study investigated the effectiveness of treatment regimens containing C‐mab for oral cancer and adverse reactions to these regimens. C‐mab is a crucial component of oral cancer treatment when used in multidrug therapy. C‐mab containing regimens may result in direct or indirect AEs. Ongoing, rigorous monitoring is essential to mitigate these events. Partnering with other departments can help to limit their severity.
- 22 May 2024
- Published by Wiley in Oral Science International
- Vol. 21 (3) , 528-537
Hyalinizing clear cell carcinoma of the base of tongue: A case report with distant metastasis
Background: Hyalinizing clear cell carcinoma (HCCC) is a rare, typically low‐grade malignant salivary gland tumor. We present a case of HCCC with multiple metastasis. Case Presentation: The patient was a 34‐year‐old woman with a tumor at the base of tongue. HCCC was diagnosed by FISH analysis for EWSR1‐ATF1 rearrangement after surgery. Systematic metastasis was identified at a three‐year follow‐up. Signs of Rouviere lymph metastasis and distant metastases (i.e., pleura, mediastinum, and gluteus maximus) were identified. The patient died because her condition deteriorated with multiple metastases. Conclusion: The potential for aggressive HCCC should be considered while offering treatment.
- 22 May 2024
- Published by Wiley in Oral Science International
- Vol. 21 (3) , 528-537
Hyalinizing clear cell carcinoma of the base of tongue: A case report with distant metastasis
Background: Hyalinizing clear cell carcinoma (HCCC) is a rare, typically low‐grade malignant salivary gland tumor. We present a case of HCCC with multiple metastasis. Case Presentation: The patient was a 34‐year‐old woman with a tumor at the base of tongue. HCCC was diagnosed by FISH analysis for EWSR1‐ATF1 rearrangement after surgery. Systematic metastasis was identified at a three‐year follow‐up. Signs of Rouviere lymph metastasis and distant metastases (i.e., pleura, mediastinum, and gluteus maximus) were identified. The patient died because her condition deteriorated with multiple metastases. Conclusion: The potential for aggressive HCCC should be considered while offering treatment.